When was Strongbridge Biopharma founded?

Strongbridge Biopharma was founded in 1996 and raised its 1st funding round 18 years after it was founded.

Where is Strongbridge Biopharma located?

Strongbridge Biopharma is headquartered in Feasterville Trevose, United States. It is registered at Magnus Stenbocks vâg 22 A, 302 34 HALMSTAD.

How many employees does Strongbridge Biopharma have?

As of Jul 01, 2024, the latest employee count at Strongbridge Biopharma is 38.

Is Strongbridge Biopharma a funded company?

Strongbridge Biopharma is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Oct 30, 2014.

When was the latest funding round of Strongbridge Biopharma?

Strongbridge Biopharma's latest funding was a $***** Post IPO round on Jul 17, 2017, with participation from 1 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $421M in funding in 2026 to date.

Where does Strongbridge Biopharma rank among its competitors?

Strongbridge Biopharma ranks 12th amongst 15 active competitors, of which 2 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Spruce, which secured $50M in Oct, 2025.

Who are the top competitors of Strongbridge Biopharma?

Strongbridge Biopharma's top competitors include Ascendis Pharma, MBX Biosciences and OMass Therapeutics. Among them, Spruce secured the most recent funding round in October, 2025.

Strongbridge Biopharma - 2026 Company Profile, Team, Funding & Competitors

Strongbridge Biopharma is an acquired company based in Feasterville Trevose (United States), founded in 1996 by Per Marin. It operates as a Developer of drugs for the treatment of rare endocrine disorders. Strongbridge Biopharma has raised an undisclosed amount in funding. The company has 15 active competitors, including 2 funded and 9 that have exited. Its top competitors include companies like Ascendis Pharma, MBX Biosciences and OMass Therapeutics.

Company Details

Developer of drugs for the treatment of rare endocrine disorders. Its lead product COR-003 levoketoconazole is a cortisol synthesis inhibitor that helps in the treatment of endogenous Cushing’s syndrome. Other product includes COR-005 is a somatostatin analog (SSA) for the treatment of patients with acromegaly, and KEVEYIS for Periodic Paralysis.

Website: www.strongbridgebio.com
Email ID: *****@strongbridgebio.com
Registered Address: Magnus Stenbocks vâg 22 A, 302 34 HALMSTAD

Key Metrics

Founded Year

1996

Location

Feasterville Trevose, United States

Stage

Acquired

Latest Funding Round

Post IPO, Jul 17, 2017, $*****

Investors

Boxer Capital & 14 more

Ranked

12^th among 15 active competitors

Employee Count

38 as on Jul 01, 2024

Similar Companies

Ascendis Pharma & 14 more

Exit Details

Acquired by Xeris Pharmaceuticals (May 24, 2021)

View Strongbridge Biopharma's full profile

Strongbridge Biopharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cortendo Invest Ab CIN: 992718633 , Norway, Active	Oct 05, 1996	-	-

Strongbridge Biopharma got acquired by Xeris Pharmaceuticals on May 24, 2021 at an acquisition amount of $267M. It was facilitated by SVB Securities, A&L Goodbody, Goodwin and 3 more.

Click here to take a look at Strongbridge Biopharma's acquisition in detail

Strongbridge Biopharma has raised funding over 7 rounds. Its first funding round was on Oct 30, 2014. Its latest funding round was a Post IPO round on Jul 17, 2017 for $*****. 1 investor participated in its latest round. Strongbridge Biopharma has 15 institutional investors.

Here is the list of recent funding rounds of Strongbridge Biopharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2017	3627091	Post IPO	3526657	4109615	5507076	2394147
Dec 22, 2016	9995096	Post IPO	9561248	2227397	9979379	Vivo Capital & 4 more
Aug 28, 2015	9481741	Post IPO	6579171	3160936	7756662	7550893

Access funding benchmarks and valuations. Sign up today!

View details of Strongbridge Biopharma's funding rounds and investors

The founders of Strongbridge Biopharma is Per Marin.

Here are the details of Strongbridge Biopharma's key team members:

Per Marin: Founder of Strongbridge Biopharma.

View details of Strongbridge Biopharma's Founder profiles and Board Members

Strongbridge Biopharma's employee count trend

Strongbridge Biopharma has 38 employees as of Jul 24. Here is Strongbridge Biopharma's employee count trend over the years:

Employee count trend for Strongbridge Biopharma

Uncover Strongbridge Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Strongbridge Biopharma include Ascendis Pharma, MBX Biosciences and OMass Therapeutics. Here is the list of Top 10 competitors of Strongbridge Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ascendis Pharma 2007, Hellerup (Denmark), Public	Integrated biopharmaceutical company to advance its pipeline of long-acting prodrug therapies	$109M	Sofinnova Investments, Vivo Capital & 14 others	64/100
2nd	MBX Biosciences 2018, Carmel (United States), Public	Developer of drugs for the treatment of rare endocrine diseases	$216M	Wellington, Deep Track Capital & 9 others	61/100
3rd	OMass Therapeutics 2016, Oxford (United Kingdom), Series B	Developer of therapeutics for immunological and orphan diseases	$166M	Sanofi Ventures, Northpond Ventures & 6 others	57/100
4th	Spruce Biosciences 2014, San Francisco (United States), Public	Clinical stage biopharma developing rare diseases affecting the stress pathway (HPA axis)	$108M	Omega Funds, Abingworth & 10 others	51/100
5th	Sigilon 2015, Cambridge (United States), Acquired	Developer of therapeutics to treat chronic diseases	$104M	CPP Investments, BlackRock & 5 others	50/100
6th	Amolyt Pharma 2015, Ecully (France), Acquired	Developer of peptide therapeutics to treat rare endocrine and metabolic disorders	$292M	Sectoral, Life Sciences Partners & 23 others	48/100
7th	Diurnal 2004, Cardiff (United Kingdom), Acquired	Developer of hormone therapeutics for the treatment of rare and chronic endocrine diseases	$10.1M	Pfizer, IP Group	47/100
8th	Spruce 2016, San Francisco (United States), Public	Developer of therapies for rare endocrine disorders	-	Armistice Capital, RiverVest Venture Partners ... & 5 others	46/100
9th	Cosciens Biopharma 2002, Summerville (United States), Public	Developer of of pharmaceutical and diagnostic products	-	HealthCare Royalty Partners	45/100
10th	Egetis 2020, Stockholm (Sweden), Funding Raised	Developer of therapeutics for rare and other diseases	-	Petrichor, Vermögensclub & 4 others	45/100
12th	Strongbridge Biopharma 1996, Feasterville Trevose (United States), Acquired	Developer of drugs for the treatment of rare endocrine disorders	-	Boxer Capital, RA Capital Management & 13 others	36/100